We are thrilled to announce a new investment from Bristol Myers Squibb, in addition to the appointment of industry veteran Greg Fralish as Chief Business Officer. The investment from BMS will further unlock the potential of the GlycoEra platform in #targetedproteindegradation as we work toward bringing novel treatments to people living with autoimmune diseases. Furthermore, we look forward to Dr. Fralish joining our team. As an experienced leader in business development across large pharma and biotech, he brings a wealth of knowledge in executing strategic initiatives and partnerships. #TPD #newinvestor #BMS #extracellularproteindegradation
Congrats to the entire team!
Congratulations on these exciting updates! The support from BMS will undoubtedly accelerate the progress of the GlycoEra platform. Looking forward to witnessing the positive impact of these developments! 🚀